Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
2 evidence topics · 2 sources
Summary
The Chinese expert consensus reports no preferred standard regimen for relapsed or refractory PCNSL. Long-term survivor evidence links whole-brain radiotherapy with greater T2 abnormalities and poorer neuropsychological and quality-of-life outcomes. Thus, treatment selection must account for both disease control and treatment-related neurological burden; the cited survivorship findings do not establish the comparative safety of tirabrutinib.